Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LEU 001

Next Previous
X
Search
Drug Profile

LEU 001

Alternative Names: Autologous CAR T-cell therapy - Leucid Bio; LEU-001

Latest Information Update: 16 Mar 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leucid Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Head and neck cancer

Most Recent Events

  • 20 May 2018 Efficacy and adverse events data from a phase I/II trial in Head and neck cancer presented at the 2018 American Society of Clinical Oncology Annual Meeting (ASCO-2018)
  • 30 Jun 2015 Phase-I/II clinical trials in Head and neck cancer (Second-line therapy or greater, Metastatic disease, Late-stage disease, Recurrent) in United Kingdom (Intratumoural) (NCT01818323) (Leucid Bio pipeline, February 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top